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Abstract
Background: More than 60% of women diagnosed with early stage breast cancer receive (neo)adjuvant
chemotherapy. Breast cancer patients receiving chemotherapy often experience symptoms such as nausea,
vomiting and loss of appetite that potentially affect body weight and body composition. Changes in body weight
and body composition may detrimentally affect their quality of life, and could potentially increase the risk of
disease recurrence, cardiovascular disease and diabetes. To date, from existing single method (quantitative or
qualitative) studies is not clear whether changes in body weight and body composition in breast cancer patients
are treatment related because previous studies have not included a control group of women without breast cancer.
Methods: We therefore developed the COBRA-study (Change Of Body composition in BReast cancer: All-in
Assessment-study) to assess changes in body weight, body composition and related lifestyle factors such as
changes in physical activity, dietary intake and other behaviours. Important and unique features of the COBRA-
study is that it used I) a “Mixed Methods Design”, in order to quantitatively assess changes in body weight, body
composition and lifestyle factors and, to qualitatively assess how perceptions of women may have influenced
these measured changes pre-, during and post-chemotherapy, and II) a control group of non-cancer women for
comparison. Descriptive statistics on individual quantitative data were combined with results from a thematic
analysis on the interviews- and focus group data to understand patients’ experiences before, during and after
chemotherapy.
Discussion: The findings of our mixed methods study, on chemotherapy treated cancer patients and a comparison
group, can enable healthcare researchers and professionals to develop tailored intervention schemes to help breast
cancer patients prevent or handle the physical and mental changes they experience as a result of their
chemotherapy. This will ultimately improve their quality of life and could potentially reduce their risk for other
co-morbidity health issues such as cardiovascular disease and diabetes.
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Background
Breast cancer is the most common cancer in women
worldwide and makes up to 25% of all female cancers
[1]. Due to early detection through screening programs
and therapeutic improvements, the five-year survival
rate in the Netherlands has increased from 78 to 88%
during the last two decades [2–5]. This implies that the
number of breast cancer survivors will steadily increase
in the future. The impact of chemotherapy on general
health, therefore becomes more important to the health
care system.
For breast cancer patients, the side-effects of chemo-
therapy can be both short- and long term. Regularly re-
ported short-term side-effects include; nausea, vomiting,
hair loss, loss of energy and fatigue [6], taste and smell
alterations [7–11] psychological distress [12–14] and even
chemotherapy-related-hospitalizations [15]. Long-term
side-effects of chemotherapy include; psychological dis-
tress and physical effects such as fatigue and loss of en-
ergy, weight gain [16–18], and unfavourable changes in
body composition (increase in fat mass and loss of muscle
mass) [17, 19–21] and loss of muscle strength [22, 23].
Weight gain and changes in body composition may have a
profound negative influence on quality of life and
self-esteem in breast cancer survivors and may also in-
crease the risk of several co-morbidities, such as
cardio-vascular disease [24, 25], diabetes [26] and breast
cancer recurrence [27–30]. Gaining a better understand-
ing of the processes that underlie these short- and
long-term side effects is critical to enable the development
of tailored intervention schemes.
To date, studies on these short- and long-term side ef-
fects have had relatively insular focuses. Several studies re-
ported that chemotherapy is associated with weight gain.
The earlier studies report large weight changes [31, 32],
while the more recent reports suggest less weight gain
[17–19]. In our meta-analysis [33] we found an overall
body weight increase during chemotherapy of 2,7 kg (95%
CI 2.0, 7.5) with a high degree of variation: some women
gain more than 10 kg while others lose weight. Changes in
body weight, body composition and muscle strength
among women with breast cancer undergoing chemother-
apy were possible influenced by lifestyle factors, such as
physical activity and dietary intake and the perception of
women on these factors.
Patients are often forced to adapt their daily activities
during treatment [34]. Several studies suggest that re-
ductions in physical activity during chemotherapy may
contribute to weight gain [9, 21, 35], lower quality of
life [36] and increase the risk of disease recurrence
[37–40]. Women may be influenced in their decision to
engage in physical activity in a negative way [41] e.g.
through pressure from friends and family to rest and
not to be active [41], or due to lack of time because of
taking care of children [42], lack of motivation [43], the
side effects of chemotherapy [44], the need to conserve
energy, fear, possible injury [45], and difficulty to stay
focused during physical activity because of “chemo brain”
[46]. When breast cancer patients tried to be more physic-
ally active during therapy however, most of them experi-
enced increased wellbeing and restored energy levels
during physical activity [47].
Reports on the influence of changes in dietary intake
during chemotherapy in cancer patients and how these
changes influence their body weight and body compos-
ition, both short and long term, vary widely. The literature
findings describe that: they showed no changes [7, 21, 48],
increases [49]), or decreases [32, 50] in energy intake
during chemotherapy. These variations could be due to
the different designs of the studies and time points of
measurements.
In a recent study by our research group [51] a 10%
lower energy intake through dietary changes (including
an absolute lower intake of protein, fat and alcohol) for
women with breast cancer, was observed during chemo-
therapy treatment (n = 117) based on 24 h recalls [51].
Furthermore, these breast cancer patients scored signifi-
cantly lower on their self-reported taste, smell, appetite
and hunger questionnaires. These results could poten-
tially be due to chemotherapy induced symptoms such
as, a dry mouth, lack of energy, nausea and difficulties
with chewing [51]. In qualitative studies, patients with
breast cancer stated during interviews that they also ex-
perienced a decreased enjoyment of food and a change
in the role of food: eating for the sake of eating and use
of comfort food as a reward, because of these changes in
taste and smell [52].
Symptoms of psychological distress are twice as high
among breast cancer patients in comparison with the
general female population. The impact of breast cancer
may have a long-term effect, extending for years after
diagnosis [53, 54]. Dealing with the diagnosis ‘breast
cancer’ could have a profound influence on their percep-
tions on changes in body composition and weight re-
lated lifestyle factors. Despite available information and
guidelines, studies suggest that women hardly experience
support in their struggle to deal with the diagnosis and
treatment [55–58]. Many women experience psycho-
logical stress and impaired quality of life as a result of a
breast cancer diagnosis and treatment [6, 13, 59, 60].
Studies suggest that women’s overall health and their al-
tered bodies are constant reminders of their illness and
its treatment [9, 16, 52, 55–58, 61–64]. Women reported
that they feel frustrated not being able to control their
weight [63] and their dietary intake [52]. Although for
most women weight management during treatment has
lower priority [65], they have to cope psychologically
with their diagnosis and the effects of the treatment.
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From the current literature, it is clear that for breast
cancer patients, the side-effects of chemotherapy can be
both short- and long term. Our understanding of the pro-
cesses that underlie these short- and long-term side effects
is however, still incomplete. In what way the patients´ per-
ceptions on lifestyle factors, such as changes in physical
activity and dietary intake, influence changes in the body
weight and body composition of breast cancer patients is
inconsistent and unclear. Furthermore, to date, the major-
ity of these previous studies [7, 17, 19, 21, 63] only
assessed changes in patients undergoing chemotherapy
during treatment and did not include a comparison group
of women without breast cancer.
We developed the COBRA study to objectively assess
changes in body weight and body composition and related
lifestyle factors and how perceptions of patients influence
these factors.). A unique feature of the COBRA study is
that it was designed as a longitudinal “Mixed Methods
Study” combining both quantitative and qualitative re-
search methods and data. The publications of the COBRA
study thus far focused on the quantitative design and
quantitative findings of the study (33). The main aim of
this manuscript is to describe the methodological design
of the qualitative part of the COBRA-study and how the
quantitative and qualitative data can be combined in a
mixed-methods approach. This enables us to not only
quantitatively assess changes in body weight and body
composition and related lifestyle factors, but also to quali-
tative assess how perceptions of breast cancer patients in-
fluence these factors not only during chemotherapy, but
also pre-, and post-chemotherapy. Furthermore, a group
of women without breast cancer are also assessed as a
comparison group, the majority of studies so far did not
include a comparison group, to evaluate the significance
of the breast cancer patient’s results.
Design and methods
To prepare the study protocol, we conducted a qualita-
tive pilot study among 20 breast cancer patients who
had already completed their chemotherapy, in order to
gain insight into their experiences with diagnosis and
treatment. We learned from these patients that their ex-
perience of having cancer influenced their attitude to-
wards quality of life, physical activity and nutrition,
beyond the direct effects of chemotherapy such as nau-
sea, vomiting, hair loss and loss of energy. Results from
the pilot study showed that all breast cancer patients
expressed an urgent need for information concerning
nutrition and physical activity during chemotherapy.
The pilot study also suggested different results based on
age and BMI group; older women and women with BMI
> 25 kg/m2 had a less urgent need for this information
and they were physically less active when compared to
younger women or women with a BMI < 25 kg/m2. We
also found that women were sometimes able to come
up with solutions to meet their own needs when they
were confronted with changes in dietary intake, phys-
ical activity and quality of life during chemotherapy.
These pilot study results confirmed the relevance of
performing an in-depth study because patients expressed
an urgent need for information about nutrition and phys-
ical activity.
Mixed-method design
We designed a longitudinal observational, mixed-method
approach, to understand patients’ experiences before, dur-
ing and after chemotherapy, using repeated measurements
and interviews as well as focus group meetings (Table 1).
The purpose of pairing qualitative and quantitative com-
ponents [66, 67] within this study is to provide a better
understanding of the changes in body weight and body
composition. Qualitative measurements of the perception
of women on physical activity and dietary intake, as well
as factors related to coping with diagnosis and treatment,
can help to explain and interpret quantitative measure-
ments of the factors influencing changes in body weight
and body composition. A mixed method study is there-
fore, a good approach to obtain in-depth information and
knowledge of the problem (i.e. changes in body weight
and body composition) and also provides comprehensive
datasets [68]. In addition, this approach assists in increas-
ing the reliability and credibility of the findings through
the combination of quantitative and qualitative results, the
methodological triangulation [69].
For breast cancer patients, data collection took place
four times during this study; T1: pre-chemotherapy, T2:
midway chemotherapy, T3: post-chemotherapy (1–3
weeks after last chemotherapy cycle), and T4: half a
year post chemotherapy. For the non-breast cancer
(comparison) group, data collection took place at: T1:
at inclusion, T2 after 3months, T3 after 6months, T4 after
1 year. For an overview see Table 1. Approval for the
COBRA-study was obtained from the Medical Ethics Com-
mittee of the Wageningen University, The Netherlands
(ABR NL40666.081.12) and the Scientific Advisory Com-
mittee VUMC/VU.
Participants and recruitment
Two hundred patients with breast cancer, indicated for
(neo)adjuvant chemotherapy were recruited from 11 hos-
pitals in the Netherlands. Inclusion criteria were 1)
women > 18 years old, 2) newly diagnosed, non-advanced
(I-IIIA) operable breast cancer scheduled for initiating
2nd or 3rd generation adjuvant or neo-adjuvant chemo-
therapy, and 3) able to communicate in Dutch. An exclu-
sion criterion was pregnancy or intentions to become
pregnant within the study period. The comparison group
of women without any history of cancer was recruited via
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the women with breast cancer, who were asked to dis-
tribute information about the study to female friends,
acquaintances and colleagues of the same age or 2 years
younger or older. Women without cancer contacted the
researchers if they were interested in participating in
the study. We recruited 200 women for this compari-
son group. All respondents signed a written informed
consent.
For the mixed method part of the COBRA-study, a
subgroup of N = 25 breast cancer patients was selected
for the qualitative part of the study (Table 1). Purposive
sampling was applied to reach as wide a range of per-
spectives as possible, and to capture the broadest set of
information and experiences. Based on previous litera-
ture and the results from our pilot study, we used the
following criteria for this sampling: variation in age
(25-64 yr), pre- or postmenopausal status (pre n = 10, peri
n = 3, post n = 12), Body Mass Index (BMI) > 25 kg/m2
(n = 11) or < 25 (n = 14), and stage I to IIIa breast cancer.
With the exception of the last criteria, the comparison
group of women without breast cancer (n = 15) were se-
lected using the same criteria.
Data collection used for the mixed method study
Quantitative data collection
Body composition, body weight and dietary intake were
assessed using: 1) a total body Dual-Energy X-ray absorp-
tiometry (DEXA) scan, 2) a Food Frequency Question-
naire (FFQ) [70] on energy intake, 3) two telephone-based
24-h dietary recalls during chemotherapy for actual diet-
ary intake because of the expected high day to day vari-
ation during chemotherapy treatment and, 4) the Appetite
Table 1 An overview of all measurements and timing of the COBRA mixed method study
Time Quantitative measurements
General questionnaire
Body composition, body weight,
muscle strength
Energy intake (FFQ) and taste
and smell
Physical activity2
Quality of life, fatigue, depressive
symptoms
Quantitative
measurements
Energy intake
taste and smell,
24 h recall1,
Qualitative
measurements
Interviews *
Qualitative
measurements
focus group
meetings**
Women with early breast cancer
n = 200
T1 pre CT x X (n = 25)
T2 mid-way CT x x
T3 post CT x x
T4 6 months post CT x x
T5 1 yr. post CT x
Women without breast cancer
Comparison group n = 200
T1 inclusion x X (n = 15)
T2 after 3 months x
T3 after 6 months x
T4 after 12 months x x
1at two randomly chosen days during CT
2accelerometer recordings over a 7 days period
*in a sample of participants (see text for a further description of details)
**focus groups with interviewed and non-interviewed participants
Kruif et al. BMC Cancer            (2019) 19:7 Page 4 of 8
Hunger Feelings and Sensory Perception Questionnaire
(AHSP) [71] on appetite, hunger, taste and smell which
was assessed with additional questions about the sever-
ity of 13 key symptoms that often occur during chemo-
therapy. Physical activity level was assessed by the
Dutch Short Questionnaire to Assess Health-enhancing
physical activity (SQUASH) [72] and by an accelerometer
which the women wore for 7 days. Quality of life was
assessed by the EORTC C-30 questionnaire [73], depres-
sion and anxiety by the Hospital Anxiety and Depression
Score (HADS) [74], and fatigue by the multi-Fatigue In-
ventory (MFI) [75]. See Table 1 for a description and the
timing of different measurements.
Qualitative data collection
Interviews The timing of the interviews is shown in
Table 1. Semi-structured interviews were held, guided by
a topic list based on a literature review and our pilot
study. Potential changes in aspects of dietary intake,
physical activity and quality of life from the perspective
of the participants were questioned. Patients were asked
to elaborate about these topics and to mention all issues
relevant from their own perspective. Additional ques-
tions were asked to uncover beliefs, values, and motiva-
tions that underlie individual health behaviours such as
response to diagnosis, physical and mental health, and
influences from the social environment during and after
chemotherapy. Each of the four interviews at T1, T2, T3
and T4 with every patient, builds on the previous one.
Each interview explicitly asks the women how their ex-
periences change over time. Interviews take place at pa-
tients’ homes or elsewhere, based on the preferences of
the patients.
All interviews are audiotaped and transcribed verba-
tim. Patients are asked to give feedback on a written
summary of the interview to foster validity (member
checks). The interviews with the non-breast cancer
women in the comparison group, provides us with
information to obtain a better understanding of the
perception and experiences of the patients during
treatment.
Focus groups
Focus group sessions were conducted after the inter-
views to validate, enrich and further explore the data
gathered during the interviews of the women with breast
cancer (Table 1). In these sessions, we also explored pos-
sible strategies the women use to curb identified changes
in dietary intake, physical activity, body weight and qual-
ity of life.
Since the study has an emergent design, the qualitative
study design evolves over time, and, the themes to be
discussed in the focus group sessions emerge from the
results of the previous personal interviews. For the focus
group sessions interviewed patients and non-interviewed
patients are invited and, eight to ten respondents partici-
pate in the assigned focus groups. The sessions are mod-
erated by a qualified researcher and observed by a
second member of the research team. The focus group
sessions are recorded on audiotape. The final number of
focus group sessions depends on the validation and en-
richment of the data.
Data analysis
Qualitative data
Analysis of the interview data starts during data collec-
tion. All transcripts of the interviews are analyzed using
a thematic content analysis with comparisons within and
across the interviewed respondents [76]. The qualitative
data analysis software MAXQDA (VERBI software, Mar-
burg, Germany) is used to manage the data [77]. Tran-
scripts are subsequently disentangled and divided into
fragments and open-coded. Codes are categorized by
subthemes and main themes. Relationships between the
subthemes are explored, to eventually cover the sub-
themes under the overall themes. The codes, subthemes
and themes are discussed within the research team until
consensus is reached on all the themes. Codes and (sub)-
themes are structured in a code tree. The constant com-
parison method [76] is used in order to understand the
differences, as well as similarities, between and within
women. The main results are discussed within the re-
search team to enhance the robustness of the findings.
The themes recognized are used to find answers for the
aim of the study, and to describe patterns and mecha-
nisms within the whole dataset to provide a broader
overview of the findings.
The data gathered during the individual interviews are
validated and enriched in the focus group sessions.
Combining these two methods (interviews and focus
groups) enabled us to check for inconsistencies and con-
tinuities between what was said in individual interviews
and what emerged from interactive group discussions.
Combined data
Mixed methods is an approach which draws upon the
strengths and perspectives of each method: the existence
of the natural physical world, quantitative, as well as the
reality and influence of human experience, qualitative
method [78]. The collection and analysis of both data
sets is carried out separately and the findings are not
compared or consolidated until the interpretation stage,
and finally sequential data analysis. The data are ana-
lyzed in a particular sequence with the use of, or find-
ings from, the other method [79]. Quantitative results
obtained from the measurements and questionnaires
(Table 1) are combined with the qualitative results ob-
tained from the individual interviews and focus group
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sessions. Together, these data sets can provide a more
complete and comprehensive evaluation of the changes
in body weight and body composition [80]. Findings
generated by the different data collection methods could
elucidate aspects of the changes in body weight and
body composition allowing us to explore the outcome
from the analysis, whether that be convergent, where
qualitative and quantitative findings lead to the same
conclusion; complementary, where qualitative and quan-
titative results can be used to supplement each other or;
divergent, where the combination of qualitative and
quantitative results provides different (and at times
contradictory) findings [69, 81].
In this study the quantitative part describes how the
body changes during chemotherapy and the period
thereafter (biomedical changes). The qualitative part fo-
cuses on how women experience potential changes in
their body and what role eating and exercise behaviour
plays (lifestyle changes). The combination of these two
parts (quantitative and qualitative) makes it possible to
explain and interpret these body and lifestyle (dietary
and physical activity) changes in order to better under-
stand changes in body weight and body composition
[80]. Descriptive results of the quantitative measure-
ments such as body weight, body composition, muscle
strength, quality of life, smell and taste, and depression
and anxiety on an individual level are linked to the re-
sults of the interviews and focus groups sessions, in
other words, are linked to the women’s perceptions on
these issues, as identified by the different themes in the
thematic analysis approach. As a result, certain potential
changes in body weight and body composition during
chemotherapy can be better understood with the help of
the perception of women on physical activity, dietary in-
take and their subsequent lifestyle behaviour.
Discussion
In this paper we describe the methodological design of
the qualitative part of the COBRA-study and how the
quantitative and qualitative data can be combined in a
mixed-methods approach. To our knowledge, this study
is the first longitudinal study in women with breast
cancer that combines both qualitative and quantitative
methodologies with measurements taken before, during
and after chemotherapy. Furthermore, it is the first
study to have a control group of non-cancer women for
comparison.
This mixed methods study focuses specifically on the
quantitative and qualitative changes in body weight and
body composition in patients with breast cancer during
chemotherapy compared to women without breast can-
cer. It explores the perceptions of women with and with-
out breast cancer and how they deal with quantitatively
measured, changes in body weight, taste and smell, dietary
intake, physical activity and quality of life.
Due to the longitudinal nature of the study, the mea-
surements and the perception and experiences of breast
cancer patients at various time points; pre-, during and
post chemotherapy treatment; can be better understood.
Specific time points at which additional support for
women is required can be evaluated and defined. The
collection of both qualitative and quantitative data facili-
tates a more complete insight and a better understand-
ing of the changes in body weight, body composition
and muscle strength.
The findings of this study will help researchers, health
care professionals and the breast cancer patients them-
selves to understand the struggles women with breast
cancer undergoing chemotherapy have, and their needs
during their treatment. This information will enable
health care professionals to develop practicable, feasible
and tailored interventions that could help breast cancer
patients to handle or prevent treatment/weight related
lifestyle changes and ultimately improve their quality of
life and future health.
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